Astrazeneca Pharma India Ltd vs Themis Medicare Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 06, 2026

Key Highlights

The Latest Trading Price of Astrazeneca Pharma India Ltd is ₹ 8369 as of 06 May 15:30 . The P/E Ratio of Astrazeneca Pharma India Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Themis Medicare Ltd changed from 7.2 on March 2021 to 45.3 on March 2025 . This represents a CAGR of 44.46% over 5 years The Market Cap of Astrazeneca Pharma India Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Market Cap of Themis Medicare Ltd changed from ₹ 257.55 crore on March 2021 to ₹ 1349 crore on March 2025 . This represents a CAGR of 39.28% over 5 years The revenue of Astrazeneca Pharma India Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Themis Medicare Ltd for the Dec '25 is ₹ 96.93 crore as compare to the Sep '25 revenue of ₹ 82.97 crore. This represent the growth of 16.83% The ebitda of Astrazeneca Pharma India Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Themis Medicare Ltd for the Dec '25 is ₹ 15.73 crore as compare to the Sep '25 ebitda of ₹ 1.89 crore. This represent the growth of 732.28% The net profit of Astrazeneca Pharma India Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The net profit of Themis Medicare Ltd changed from ₹ 24.68 crore to ₹ 10.09 crore over 7 quarters. This represents a CAGR of -40.02% The Dividend Payout of Astrazeneca Pharma India Ltd changed from 5.36 % on March 2021 to 69.12 % on March 2025 . This represents a CAGR of 66.76% over 5 yearsThe Dividend Payout of Themis Medicare Ltd changed from 14.84 % on March 2021 to 19.23 % on March 2025 . This represents a CAGR of 5.32% over 5 years .

About Astrazeneca Pharma India Ltd

AstraZeneca Pharma India Limited (APIL) was incorporated on July 11, 1979.
The Company is engaged in the business of manufacture, distribution and marketing of pharmaceutical products and co-ordinates clinical trial services with an overseas group company.
The major therapy areas where the company operates are Onocology, Alimentary & Metabolism, Cardio Vascular, Renal, Diabetes, Respiratory and Oncology. AstraZeneca Pharma India, formerly known as Astra-IDL (AIL), was an erstwhile joint venture of Astra Zeneca, UK and Hinduja controlled IDL. Astra Pharmaceuticals AB, Sweden acquired all of the 1287500 equity shares in the Company of IDL, representing 25.75% of the Company's issued and paid up equity share capital.
Consequently, the Company became a subsidiary of Astra, which is a direct wholly owned subsidiary of Astra AB, Sweden (now known as AstraZeneca Pharmaceuticals AB Sweden) and an indirect wholly owned subsidiary of AstraZeneca Plc, the Group parent Company.

About Themis Medicare Ltd

Themis Medicare Limited was formerly incorporated as 'Themis Chemicals Limited' in 1969.
The Company was originally promoted by Chemosyn and Medimpex but was taken over by a Group consisting of Shantibhai D Patel and K T Lakdawala who also have interests in Andhra Synthetics and Antibiotics, which was merged with Artemis Pharmaceuticals in April, 1993.
Thereafter, the name of the Company was changed to Themis Medicare Limited in 2001.
The Company is principally engaged in the business of manufacturing of finished formulations and synthetic Active Pharmaceutical Ingredients. In Mar.'95, the company came out with a public issue equity shares (premium : Rs 110) to finance the expansion-cum-modernisation of its synthetic bulk drug plant at Vapi, the setting up of a formulation unit at Lilora, Baroda as backward integration and to augment long-term working capital.

FAQs for the comparison of Astrazeneca Pharma India Ltd and Themis Medicare Ltd

Which company has a larger market capitalization, Astrazeneca Pharma India Ltd or Themis Medicare Ltd?

Market cap of Astrazeneca Pharma India Ltd is 20,923 Cr while Market cap of Themis Medicare Ltd is 916 Cr

What are the key factors driving the stock performance of Astrazeneca Pharma India Ltd and Themis Medicare Ltd?

The stock performance of Astrazeneca Pharma India Ltd and Themis Medicare Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Astrazeneca Pharma India Ltd and Themis Medicare Ltd?

As of May 6, 2026, the Astrazeneca Pharma India Ltd stock price is INR ₹8369.45. On the other hand, Themis Medicare Ltd stock price is INR ₹99.5.

How do dividend payouts of Astrazeneca Pharma India Ltd and Themis Medicare Ltd compare?

To compare the dividend payouts of Astrazeneca Pharma India Ltd and Themis Medicare Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.